Infliximab for Injection
Efficacy and safety are equivalent to the original drug (Johnson & Johnson/Merck & Co.
The first infliximab biosimilar marketed in China
Infliximab for Injection (Reminton), a recombinant anti-TNF-alpha chimeric monoclonal antibody, was approved for marketing by the National Medical Products Administration (NMPA) on July 14, 2021. It is the first infliximab biosimilar marketed in China. Taking advantage of CHO cell expression system, Remin_x005f ton has been proved with good efficacy, better safety, and lower immunogenicity in clinical studies.
Indications:
Crohn's disease in adults and children over 6 years of age, stulizing Crohn's disease,
ulcerative colitis in adults, ankylosing spondylitis, rheumatoid arthritis, and psoriasis.
Recommended reading
Related products
-
Quick View
Phasellus molestie id mi sit amet
$66.00Add to cartMorbi mattis ipsum sem, in gravida dolor venenatis vestibulum. Aenean laoreet, nisi in bibendum dictum, purus libero accumsan enim, id vehicula enim metus vitae ipsum. Maecenas nulla est, dictum quis augue ultrices, dictum rutrum enim. Aliquam erat volutpat.
-
Quick View
Aenean non pellentesque mauris
Original price was: $68.00.$55.00Current price is: $55.00.Add to cartNullam porttitor pharetra ullamcorper. Praesent varius erat vitae nibh laoreet cursus. Donec suscipit gravida viverra. Suspendisse consectetur ipsum augue, a varius enim tempus a. Phasellus id nibh arcu. Curabitur rutrum vehicula mi id congue. Phasellus vitae leo sodales, pretium turpis non, efficitur eros. Donec fermentum at nisi suscipit vulputate.
-
Quick View
Morbi varius ligula eget ante
Original price was: $55.00.$45.00Current price is: $45.00.Add to cartMaecenas nulla est, dictum quis augue ultrices, dictum rutrum enim. Aliquam erat volutpat. Quisque ultricies ornare lacus, eu sagittis urna euismod ac. Nulla rhoncus ultrices ligula, id maximus ligula ultricies non.
-
Quick View
Suspendisse vehicula at dui
$56.00Add to cartMorbi mattis ipsum sem, in gravida dolor venenatis vestibulum. Aenean laoreet, nisi in bibendum dictum, purus libero accumsan enim, id vehicula enim metus vitae ipsum. Maecenas nulla est, dictum quis augue ultrices, dictum rutrum enim. Aliquam erat volutpat. Quisque ultricies ornare lacus, eu sagittis urna euismod ac. Nulla rhoncus ultrices ligula, id maximus ligula ultricies non.
Reviews
There are no reviews yet.